Verve Therapeutics, Inc. (VERV): Price and Financial Metrics

Verve Therapeutics, Inc. (VERV): $40.27

0.33 (+0.83%)

POWR Rating

Component Grades













Add VERV to Watchlist
Sign Up

Industry: Biotech



in industry

VERV Stock Price Chart Interactive Chart >

Price chart for VERV

VERV Price/Volume Stats

Current price $40.27 52-week high $76.07
Prev. close $39.94 52-week low $10.70
Day low $39.31 Volume 317,980
Day high $40.79 Avg. volume 825,908
50-day MA $29.87 Dividend yield N/A
200-day MA $25.97 Market Cap 2.41B

Verve Therapeutics, Inc. (VERV) Company Bio

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.

VERV Latest News Stream

Event/Time News Detail
Loading, please wait...

VERV Latest Social Stream

Loading social stream, please wait...

View Full VERV Social Stream

Latest VERV News From Around the Web

Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.

Why Verve Therapeutics Stock Crushed It This Week

Verve Therapeutics (NASDAQ: VERV), a clinical-stage gene-editing company focusing on cardiovascular disease, saw its shares race higher this week by a healthy 17.1%, according to data from S&P Global Intelligence. Verve's shares have been rocketing higher ever since Vertex Pharmaceuticals (NASDAQ: VRTX) entered into a strategic collaboration and license agreement with the biotech for an undisclosed liver disease on July 18, 2022. Vertex reportedly made a $25 million upfront cash payment and agreed to purchase 1,519,756 shares of Verve's common stock at a price of $23.03 per share as part of this liver disease collaboration.

Yahoo | August 27, 2022

Verve Therapeutics Posts Updated Preclinical Data For Gene-Editing Therapy In Cardiovascular Disease

Verve Therapeutics Inc (NASDAQ: VERV) announced new preclinical data supporting the nomination of the company's second product candidate, VERVE-201. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism. Verve is initially developing VERVE-201 for homozygous familial hypercholesterolemia (HoFH), a rare genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood low-densit

Yahoo | August 22, 2022

Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress

CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination of the company’s second product candidate, VERVE-201. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism, with a precise A-to-G

Yahoo | August 22, 2022

Ending Bad Cholesterol With a Single Injection—an Opportunity for Brave Investors

Verve’s effort to lower patients’ levels of bad cholesterol with a single injection is gradually making clinical progress and would be a significant upgrade from statins and other medicines currently available.

Yahoo | August 18, 2022

BMO Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Verve Therapeutics (VERV - Research Report) today and set a price target of $62.00. The company's shares opened today at $29.42.According to TipRanks, Biliouris is a 4-star analyst with an average return of 30.8% and a 72.73% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Crispr Therapeutics AG, and Beam Therapeutics.Currently, the analyst consensus on Verve Therapeutics is a Strong Buy with an average price target of $57.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $78.00 and a one-year low of $10.70.

Austin Angelo on TipRanks | August 10, 2022

Read More 'VERV' Stories Here

VERV Price Returns

1-mo 42.10%
3-mo 219.35%
6-mo 53.29%
1-year -42.53%
3-year N/A
5-year N/A
YTD 9.22%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7123 seconds.